MedTrace Logo

Memantine for Agitation in Dementia

NCT00371059 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2022-04-06

No results posted yet for this study

Summary

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Conditions

Interventions

DRUG

Memantine

Memantine 10mg BD

DRUG

Placebo

Placebo 10 mgs BD

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Institute of Psychiatry, London

    collaborator OTHER

  • University of London

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • Indiana University School of Medicine

    collaborator OTHER

  • East Kent Hospitals University NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • CHRIS FOX, MBBSBscMSC · KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371059 on ClinicalTrials.gov